Escitalopram Discontinuation Symptoms and Duration
Escitalopram can cause discontinuation syndrome with symptoms including dizziness, sensory disturbances (electric shock sensations/paresthesias), anxiety, irritability, confusion, headache, nausea, insomnia, and emotional lability—these symptoms are generally self-limiting and typically last 1-2 weeks, though they can occasionally persist for months. 1
Specific Discontinuation Symptoms
The FDA label for Lexapro (escitalopram) identifies the following discontinuation symptoms that occur particularly with abrupt cessation 1:
Neurological symptoms:
- Dizziness (reported in 44% of cases) 2
- Sensory disturbances, particularly paresthesias described as "electric shock sensations" or "brain zaps"
- Headache
- Confusion or trouble concentrating (40% of cases) 2
- Amnesia (28% of cases) 2
Psychiatric symptoms:
- Anxiety
- Irritability and agitation
- Dysphoric mood
- Emotional lability and crying (28% of cases) 2
- Insomnia
- Hypomania (rare)
Physical symptoms:
Duration of Symptoms
The typical timeline is 1-2 weeks for most patients 3, with symptoms usually beginning within a few days of discontinuation. However, important caveats exist:
- While the FDA label states symptoms are "generally self-limiting" 1, research shows significant variability
- A 2016 study found that higher doses and plasma concentrations of escitalopram increase the risk of discontinuation syndrome 2
- Protracted withdrawal lasting beyond 6 weeks can occur, with some cases documented from 5 to 166 months (mean 37 months) in patients with long-term antidepressant exposure 4
Clinical Context: Escitalopram vs Other SSRIs
Escitalopram has a relatively favorable discontinuation profile compared to other SSRIs. The 2020 AACAP guidelines note that discontinuation syndrome is "notably" associated with paroxetine and "to a lesser extent" with fluvoxamine and sertraline, but does not specifically list escitalopram/citalopram among the high-risk agents 5. Research confirms escitalopram produces significantly fewer discontinuation symptoms than paroxetine and venlafaxine 6.
Prevention and Management
Gradual dose reduction is essential—abrupt cessation should be avoided 1. The FDA label explicitly recommends:
- Taper gradually rather than stopping abruptly whenever possible
- If intolerable symptoms emerge during tapering, resume the previous dose and taper more slowly
- Monitor patients closely during discontinuation 1
The 2009 AACAP practice parameter emphasizes that "prescribers are generally encouraged to taper medication slowly to avoid withdrawal symptoms" for SSRIs 7. Very slow tapering is recommended for all patients, particularly those on higher doses 2.
Critical Pitfall to Avoid
Discontinuation symptoms can be easily misidentified as relapse of the underlying depression or anxiety disorder 8. Key distinguishing features:
- Discontinuation symptoms typically begin within days of stopping/reducing medication
- Symptoms include physical manifestations (dizziness, paresthesias, flu-like symptoms) not typical of depression relapse
- Symptoms rapidly resolve with medication reinstitution 3
- True relapse typically occurs weeks to months after discontinuation 7
Risk Factors
Higher risk of discontinuation syndrome occurs with 2, 3:
- Higher treatment doses
- Longer duration of treatment (≥6 weeks minimum, but risk increases with longer exposure)
- Abrupt cessation rather than gradual taper
- Lower drug clearance (higher plasma concentrations)
Monitor all patients for 2-3 months after complete discontinuation, as this is the highest risk period for both discontinuation symptoms and potential relapse 9.